New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials. In an interview with Targeted Oncology, Rutika Mehta, MD, MPH ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Molecular recurrence signals preceded symptoms or imaging in all recurrences observed, indicating ctDNA may enable earlier intervention than conventional surveillance paradigms. Post-neoadjuvant ctDNA ...
SAN ANTONIO — The randomized phase 3 ZEST trial, which was aimed at evaluating niraparib (Zejula) for prevention or delay of breast cancer recurrence in patients with minimal residual disease (MRD) ...
Learn how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising ctDNA means before scans. In an interview with Targeted Oncology, Rutika Mehta, MD ...
ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...
ctDNA monitoring in esophageal and gastroesophageal cancers may detect recurrence earlier than traditional methods, offering a minimally invasive and sensitive approach. The Signatera assay showed ...
—Tumor-informed circulating tumor DNA testing was shown to be highly sensitive for monitoring patients with metastatic breast cancer receiving standard-of-care therapy. Circulating tumor DNA (ctDNA) ...
Stocktwits on MSN
Why VNRX Stock Is Soaring Over 70% In Pre-Market Today?
Shares of VolitionRx (VNRX) surged more than 70% in pre-market trading on Wednesday after the diagnostics company unveiled what it called a potential breakthrough in cancer detection. The company said ...
Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small cell lung cancer with ctDNA positivity after chemotherapy had significant ...
Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, ...
For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results